TAK financial statements
The full income statement, balance sheet, and cash-flow statement for Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK), plus valuation ratios — straight from SEC filings. Switch between annual, quarterly, and trailing-twelve-month figures, pick how far back to look, and flip the time order. Every line has a trend sparkline.
Shares outstanding (point-in-time)
SEC-filed end-of-period counts (cover pages and balance sheets, split-adjusted) — the series realized buyback yield is computed from. The weighted-average share lines in the statements below lag these by design: an average over the year sits near the midpoint of an ongoing buyback.
| Line item | Trend | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|---|
| Income Statement | as ofMar 31 ’26 | as ofMar 31 ’25 | as ofMar 31 ’24 | as ofMar 31 ’23 | as ofMar 31 ’22 | |
| Revenue | 29.8B-0.9% | 30.0B+2.0% | 29.5B-1.0% | 29.7B-6.4% | 31.8B+5.3% | |
| Cost of revenue | 10.4B+0.3% | 10.4B+5.1% | 9.86B+7.3% | 9.19B-6.7% | 9.85B+5.0% | |
| Research & development | 4.47B-6.7% | 4.79B-5.0% | 5.04B+7.8% | 4.68B-0.1% | 4.68B+8.9% | |
| Operating income | 41.1M-98.2% | 2.25B+51.9% | 1.48B-59.2% | 3.62B-11.7% | 4.10B-14.6% | |
| Interest expense | 2.36B+71.6% | 1.38B-9.3% | 1.52B+21.2% | 1.25B-15.5% | 1.48B-36.8% | |
| Pre-tax income | -941M-182.0% | 1.15B+214.8% | 365M-86.8% | 2.77B+2.9% | 2.69B-22.1% | |
| Income tax | 64.6M-85.3% | 439M+169.5% | -631M-247.3% | 429M-33.5% | 644M+787.5% | |
| -1.01B-241.8% | 709M-28.8% | 996M-57.5% | 2.34B+14.3% | 2.05B-42.3% | ||
| Net income to common | -1.01B-242.3% | 708M-28.9% | 995M-57.5% | 2.34B+14.3% | 2.05B-42.3% | |
| -$0.32-245.1% | $0.22-30.0% | $0.31-57.8% | $0.75+14.9% | $0.65-42.4% | ||
| EPS (basic) | -$0.32-242.7% | $0.22-29.5% | $0.32-57.8% | $0.75+15.2% | $0.65-42.3% | |
| Weighted-avg shares (basic) | 3.15B-0.2% | 3.16B+0.9% | 3.13B+0.8% | 3.10B-0.7% | 3.13B+0.1% | |
| Weighted-avg shares (diluted) | 3.15B-1.9% | 3.21B+1.6% | 3.16B+0.7% | 3.14B-0.5% | 3.15B+0.2% | |
| Dividends per share | $0.66+5.0% | $0.62-0.5% | $0.63-3.3% | $0.65-18.8% | $0.80-5.9% | |
| Balance Sheet | as ofMar 31 ’26 | as ofMar 31 ’25 | as ofMar 31 ’24 | as ofMar 31 ’23 | as ofMar 31 ’22 | |
| 19.5B+15.8% | 16.8B-0.5% | 16.9B-6.5% | 18.1B-15.2% | 21.3B-13.3% | ||
| Cash & equivalents | 3.75B+46.0% | 2.57B-15.1% | 3.02B-24.8% | 4.02B-42.4% | 6.98B-20.2% | |
| Accounts receivable | 5.32B+12.4% | 4.73B+7.1% | 4.42B-9.8% | 4.90B-14.5% | 5.73B-19.3% | |
| Inventory | 8.80B+8.4% | 8.12B+1.6% | 7.99B+7.4% | 7.44B+6.1% | 7.01B+2.6% | |
| 97.7B+2.9% | 95.0B-4.8% | 99.8B-5.2% | 105B-2.8% | 108B-7.4% | ||
| Property, plant & equipment | — | — | — | 12.8B-2.0% | 13.0B-1.3% | |
| Goodwill | 36.6B+3.1% | 35.5B-0.7% | 35.7B-1.1% | 36.1B-0.3% | 36.2B-0.9% | |
| Total non-current assets | 78.3B+0.1% | 78.2B-5.7% | 82.9B-4.9% | 87.2B+0.2% | 87.0B-5.9% | |
| Total current liabilities | 17.8B+6.8% | 16.7B+9.4% | 15.3B-18.4% | 18.7B+6.1% | 17.6B+9.8% | |
| 50.9B+4.4% | 48.8B-5.8% | 51.8B-9.7% | 57.3B-6.9% | 61.6B-12.1% | ||
| Long-term debt | 27.5B+4.1% | 26.4B-10.6% | 29.6B-3.0% | 30.5B-10.4% | 34.0B-18.6% | |
| 46.8B+1.2% | 46.2B-3.7% | 48.0B+0.3% | 47.9B+2.6% | 46.7B-0.4% | ||
| Total equity incl. non-controlling | 46.8B+1.2% | 46.3B-3.7% | 48.1B+0.3% | 47.9B+2.5% | 46.7B-0.4% | |
| Common shares outstanding | — | 3.18B+0.5% | 3.16B+0.0% | 3.16B+0.0% | 3.16B+0.4% | |
| Cash Flow | as ofMar 31 ’26 | as ofMar 31 ’25 | as ofMar 31 ’24 | as ofMar 31 ’23 | as ofMar 31 ’22 | |
| 6.88B-0.7% | 6.93B+40.1% | 4.95B-31.4% | 7.22B-27.8% | 9.99B+4.8% | ||
| Depreciation & amortization | 4.77B-4.5% | 4.99B-0.7% | 5.03B+2.5% | 4.91B-5.5% | 5.19B-1.7% | |
| Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Long-term debt issued | 3.87B-42.3% | 6.72B+872.5% | 691M+24.7% | 554M-75.0% | 2.22B-80.1% | |
| Long-term debt repaid | 1.33B-84.7% | 8.66B+290.8% | 2.22B-15.8% | 2.63B-63.5% | 7.21B-53.7% | |
| Common stock issued | 7.84M-96.7% | 237M+6741.3% | 3.47M+186.3% | 1.21M-99.4% | 197M+47400.1% | |
| Common stock repurchased | 341M+0.3% | 340M+1982.4% | 16.4M-91.8% | 200M-71.7% | 707M+3400.7% | |
| Dividends paid | 2.07B+3.9% | 1.99B-0.0% | 1.99B-3.3% | 2.06B-18.7% | 2.53B-5.5% | |
| Valuation Ratios | as ofMar 31 ’26 | as ofMar 31 ’25 | as ofMar 31 ’24 | as ofMar 31 ’23 | as ofMar 31 ’22 | |
| Market cap | 58.3B+23.3% | 47.3B+7.6% | 44.0B-15.7% | 52.2B+15.1% | 45.3B-21.3% | |
| P/E | — | 66.7×+255.4% | 18.8×-15.7% | 22.3×+0.7% | 22.1×+36.4% | |
| P/S | 2.0×+24.4% | 1.6×+6.6% | 1.5×-15.7% | 1.8×+22.9% | 1.4×-25.2% | |
| P/B | 1.2×+21.8% | 1.0×+11.5% | 0.9×-15.7% | 1.1×+12.2% | 1.0×-21.0% | |
| Earnings yield | — | 1.5%-71.9% | 5.3%+18.6% | 4.5%-0.7% | 4.5%-26.7% | |
| Dividend yield | 3.5%-15.7% | 4.2%-7.1% | 4.5%+14.8% | 3.9%-29.4% | 5.6%+20.0% | |
| Source filing | 20-F | 20-F | 20-F | 20-F | 20-F |
About this data
Source: TAK’s SEC filings (10-K / 10-Q). Annual columns are as-reported fiscal years; quarterly columns are as-reported fiscal quarters (Q4 derived as full-year minus the first three quarters where a company doesn’t file a standalone Q4); TTM (quarterly) rolls the trailing four quarters at every quarter end, TTM (yearly) samples that one year apart; balance-sheet rows show the period-end balance. Valuation ratios are sampled as of each period end. View all TAK filings on SEC EDGAR → Not investment advice.